SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc.’s Chief Financial Officer Anshul Maheshwari reported a mix of equity awards and related share sales. On February 16, 2026, he acquired a total of 107,992 shares of common stock through grants of restricted stock units, which vest over multi‑year periods based on time and total shareholder return performance.
On February 17, 2026, he sold 21,528 shares of common stock in multiple open‑market transactions at prices between $15.18 and $15.62. Footnotes state these sales were solely to cover tax withholding obligations from RSU vesting under a sell‑to‑cover arrangement and were not discretionary trades.
OrbiMed Capital LLC and OrbiMed Advisors LLC report that they no longer own any shares of SI-BONE, Inc. common stock. As of the event date of 12/31/2025, each reporting person discloses beneficial ownership of 0 shares, representing 0.0% of SI-BONE’s common stock.
They report no sole or shared voting or dispositive power over any SI-BONE shares and confirm they now own 5 percent or less of the class. The firms state the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
American Century entities and the Stowers Institute report significant ownership stakes in Si-Bone, Inc. common stock in an amended Schedule 13G. American Century Investment Management, American Century Companies, and the Stowers Institute each report beneficial ownership of 2,300,508 shares, representing 5.3% of the class.
American Century Mutual Funds separately reports beneficial ownership of 1,779,575 shares, or 4.1% of the common stock. The filers certify that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Si-Bone.
SI-BONE, Inc. (SIBN) received an updated Schedule 13G/A from Brown Advisory and related entities reporting their passive ownership in the company’s common stock as of 12/31/2025. Brown Advisory Inc and its listed subsidiaries report beneficial ownership of 2,513,268 shares, representing 5.79 % of the outstanding common stock.
The shares are held across multiple affiliated entities, including Brown Advisory LLC, Brown Investment Advisory & Trust, Signature Financial Management, Inc., and Brown Advisory Ltd, largely through investment companies and managed accounts. The group certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE.
Champlain Investment Partners, LLC reported beneficial ownership of 2,108,944 shares of SI-BONE, Inc. common stock, representing 4.9% of the class as of 09/30/2025. Champlain has sole voting power over 1,337,489 shares and sole dispositive power over 2,108,944 shares, with no shared voting or dispositive power.
The firm files as an institutional investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose or effect of changing or influencing control of SI-BONE, Inc.
SI-BONE, Inc. director Jeffrey W. Dunn reported a small sale of company stock tied to tax obligations. On February 2, 2026, he sold 337 shares of common stock at a weighted average price of $16.4157 per share.
The footnotes explain this was a mandatory "sell to cover" transaction to satisfy tax withholding from vesting restricted stock units, and not a discretionary trade. After the sale, Dunn beneficially owned 9,970 shares directly, including 9,491 shares issuable upon settlement of restricted stock units, and 80,115 shares indirectly held by The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
SI-BONE director Jeffrey W. Dunn, through The Jeffrey W. Dunn Living Trust Dated May 17, 2012, reported selling 20,000 shares of SI-BONE common stock on January 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated May 7, 2025 at a weighted-average price of $21.2753 per share, with individual trade prices ranging from $20.84 to $21.84.
Following the sale, the trust held 80,115 shares indirectly, while Dunn also had 10,307 shares directly, including shares issuable upon settlement of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of SI-BONE common stock.
SI-BONE, Inc. filed a current report describing that it has released a press release with preliminary unaudited revenue and cash and equivalents figures for the fourth quarter and full year 2025. These early numbers are meant to give the market an initial view of the company’s recent performance and year-end liquidity before audited results are available.
The company also plans meetings with investors and analysts, supported by a slide presentation. Both the press release and the presentation are included as exhibits and are being furnished, not filed, which means they are not automatically incorporated into other securities law filings.
SIBN received a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers a proposed sale of 60,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ market. These 60,000 shares were acquired as restricted stock units from the issuer on October 15, 2021.
Recent trading history in the notice shows that The Jeffrey W. Dunn Living Trust has already sold common shares in the past three months, including 20,000 shares for gross proceeds of 386,594.00 on December 8, 2025, 80,000 shares for 1,516,000.00 on November 11, 2025, and 293 shares for 4,337.51 on November 3, 2025. The planned and recent sales are for the account of that trust, which represents that it is not aware of undisclosed material adverse information about the issuer.
SI-BONE, Inc. executive reports tax-related share sale
SI-BONE, Inc. Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported selling small amounts of the company’s common stock on January 2, 2026. The sales, executed in three trades at prices of $19.75, $19.6811, and $19.5788 per share, were made to cover tax withholding obligations tied to the vesting of restricted stock units. According to the disclosure, this was a mandated “sell to cover” transaction and not a discretionary trade.
After these sales, Pisetsky beneficially owned 228,436 shares of SI-BONE common stock directly. This amount includes 119,679 shares that are issuable upon settlement of restricted stock units, each unit representing the right to receive one share of common stock.